NAFLD/NASH Medications

The NAFLD/NASH medications' page includes specific information about each of the experimental drugs in later phases of development for treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Quick Links

NAFLD/NASH Medications

Quick Filter

*generic or biosimilar available

E experimental

NAFLD/NASH Medications Learn more >> More >>

	DRUG	ABBRV.	GENERIC NAME
E	cenicriviroc	CVC	cenicriviroc
E	elafibranor	N/A	elafibranor
E	Ocaliva	OCA	obeticholic acid
E	selonsertib	N/A	selonsertib
E	emricasan	N/A	emricasan
E	cilofexor	N/A	N/A
E	firsocostat	N/A	N/A
E	pegbelfermin	N/A	pegbelfermin
E	tropifexor	N/A	tropifexor

Multi-Class Combination Drugs More >>

DRUG cenicriviroc
E
ABBRV. CVC
GENERIC NAME cenicriviroc

DRUG elafibranor
E
ABBRV. N/A
GENERIC NAME elafibranor

DRUG Ocaliva
E
ABBRV. OCA
GENERIC NAME obeticholic acid

DRUG selonsertib
E
ABBRV. N/A
GENERIC NAME selonsertib

DRUG emricasan
E
ABBRV. N/A
GENERIC NAME emricasan

DRUG cilofexor
E
ABBRV. N/A
GENERIC NAME N/A

DRUG firsocostat
E
ABBRV. N/A
GENERIC NAME N/A

DRUG pegbelfermin
E
ABBRV. N/A
GENERIC NAME pegbelfermin

DRUG tropifexor
E
ABBRV. N/A
GENERIC NAME tropifexor

NAFLD/NASH Medications

Quick Links

Quick Filter

NAFLD/NASH Medications Learn more >> More >>

Multi-Class Combination Drugs More >>

RELATED articles

Two Thirds of People With Overweight or Obesity Have Fatty Liver Disease

Caffeine May Reduce Severity of NAFLD in Those With Type 2 Diabetes

Liver Cancer Is Expected to Rise 55% by 2040

People With Both NAFLD and Diabetes Experience Greater Fibrosis Progression